HEALTHCARE
Global Immunotherapy Market - Industry Trends and Forecast to 2032
REPORT OVERVIEW
Global Immunotherapy Market, By Type (Immune Checkpoint Inhibitor, T-cell Transfer Therapy, Monoclonal Antibodies, Treatment Vaccines, Immune System Modulators), Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Others), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Others), Route of Administration (Intravenous, Oral, Topical, Intravesical), End-use (Hospitals, Specialty clinics, Cancer research centers), Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies), Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2032.
Market Insights
The global immunotherapy market size is valued to be USD xx million in 2023 and is expected to reach USD xx million by 2032, and it is expected to register a CAGR of xx% over the forecast period 2024-2032.
Immunotherapy is a medical intervention that either strengthens or weakens the immune system's reaction to illnesses such as allergies, autoimmune diseases, and cancer. It employs a variety of strategies, including immune response stimulation to target certain cells, tissues, or organs, and immune response suppression to control autoimmune illnesses or prevent organ rejection following transplantation. The immunotherapy market includes medicines, biologics, and treatments that modify immune responses. It covers treatments that are essential for treating cancer and are just beginning to be used in other fields, such as autoimmune disorders and infectious diseases, such as checkpoint inhibitors, monoclonal antibodies, vaccines, and cytokines. Immunotherapy is a promising new area for medical innovation and patient care as a result of rising rates of cancer and chronic illnesses around the world, which also drive market growth.
The respective global report analyses market trends, consumer behaviour and industry dynamics to guide towards entry into new markets with ease. Also, it assists in tailoring market specific and related products and services to meet the needs, preferences, and expectations of target audience by delving into their psychology. The report also specializes with comprehensive and extensive competitive analysis which offers useful insights into competitor strengths, weaknesses, opportunities, and threats. The respective report offers exclusive insights into the potential impact of disruptive developments and technologies that are expected to completely transform corporate operations. The context includes tailor-made research solutions to create a stronger footprint in their particular industries thereby offering dedicated customized solutions according to the client needs which helps in addressing unique business challenges with more simplified and efficient decision-making solutions.
Market Dynamics
DRIVERS
- Rising incidence of cancer globally.
- Advancements in biotechnology and genomics.
RESTRAINTS
- High costs associated with treatment.
- Side effects and complexities in treatment.
OPPORTUNITIES
- Expansion into emerging markets.
- Development of novel therapies.
CHALLENGES
- Resistance to immunotherapy in some patients.
- Limited awareness among patients and healthcare providers.
SEGMENTATION
- Type
- Immune Checkpoint Inhibitor
- T-cell Transfer Therapy
- Monoclonal Antibodies
- Treatment Vaccines
- Immune System Modulators
- Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head and Neck Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Others
- Indication
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Others
- Route of Administration
- Intravenous
- Oral
- Topical
- Intravesical
- End-use
- Hospitals
- Specialty clinics
- Cancer research centers
- Distribution Channel
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
The respective global report is completely customizable specific to regions (North America, Europe, Asia-Pacific, South America, Middle East and Africa), countries, and segments as per the client requirements.
REGIONAL SEGMENTATION
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- The Netherlands
- Belgium
- Turkey
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Malaysia
- Australia
- Thailand
- Philippines
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Chile
- Colombia
- Rest of South America
- Middle East and Africa
- Kingdom of Saudi Arabia
- South Africa
- U.A.E.
- Egypt
- Rest of Middle East and Africa
KEY MARKET PLAYERS
- Pfizer Inc
- Astra Zeneca
- Merck and Co
- F-Hoffman-La Roche
- Bristol Myers Squibb Company
- Novartis AG
- Lily
- Johnson and Johnson
- Immunocore
- BioNTech
Table OF CONTENTS
- SECTION 1 - INTRODUCTION
- 1.1 Taxonomy
- 1.2 Market Overview
- 1.3 Currency and Limitations
- 1.3.1 Currency
- 1.3.2 Limitations
- 1.4 Key Competitors
- SECTION 2 - RESEARCH METHODOLOGY
- 2.1 Research Approach
- 2.2 Data Collection and Validation
- 2.2.1 Secondary Research
- 2.2.2 Primary Research
- 2.3 Market Assessment
- 2.3.1 Market Size Estimation
- 2.3.2 Bottom-up Approach
- 2.3.3 Top-down Approach
- 2.3.4 Growth Forecast
- 2.4 Market Study Assumptions
- 2.5 Data Sources
- SECTION 3 - EXECUTIVE SUMMARY
- 3.1 Global Immunotherapy Market, by Type
- 3.2 Global Immunotherapy Market, by Cancer
- 3.3 Global Immunotherapy Market, by Indication
- 3.4 Global Immunotherapy Market, by Route of Administration
- 3.5 Global Immunotherapy Market, by End-use
- 3.6 Global Immunotherapy Market, by Distribution Channel
- 3.7 Global Immunotherapy Market, by Geography
- 3.8 Market Position Grid
- SECTION 4 - PREMIUM INSIGHTS
- 4.1 Regulatory Framework
- 4.1.1 Standards
- 4.1.2 Regulatory Landscape
- 4.2 Value Chain Analysis
- 4.3 Supply Chain Analysis
- 4.4 COVID-19 Impact
- 4.5 Russia-Ukraine War Impact
- 4.6 PORTER's Five Force Analysis
- 4.7 PESTLE Analysis
- 4.8 SWOT Analysis
- 4.9 Go to Market Strategy
- 4.10 Opportunity Orbit
- 4.11 Multivariate Modelling
- 4.12 Pricing Analysis
- SECTION 5 - MARKET DYNAMICS
- 5.1 Trends
- 5.1.1 Growing adoption of immune checkpoint inhibitors.
- 5.1.2 Increasing research in combination therapies.
- 5.1.3 Trend 3
- 5.2 Drivers
- 5.2.1 Rising incidence of cancer globally.
- 5.2.2 Advancements in biotechnology and genomics.
- 5.2.3 Driver 3
- 5.2.4 Driver 4
- 5.3 Restraints
- 5.3.1 High costs associated with treatment.
- 5.3.2 Side effects and complexities in treatment.
- 5.3.3 Restraint 3
- 5.4 Opportunities
- 5.4.1 Expansion into emerging markets.
- 5.4.2 Development of novel therapies.
- 5.4.3 Opportunity 3
- 5.4.4 Opportunity 4
- 5.5 Challenges
- 5.5.1 Resistance to immunotherapy in some patients.
- 5.5.2 Limited awareness among patients and healthcare providers.
- 5.5.3 Challenge 3
- SECTION 6 - GLOBAL IMMUNOTHERAPY MARKET, BY TYPE
- 6.1 Type Summary
- 6.2 Market Attractive Index
- 6.3 Global Immunotherapy Market, by Type (2019-2032)
- SECTION 7 - GLOBAL IMMUNOTHERAPY MARKET, BY CANCER
- 7.1 Cancer Summary
- 7.2 Market Attractive Index
- 7.3 Global Immunotherapy Market, by Cancer (2019-2032)
- SECTION 8 - GLOBAL IMMUNOTHERAPY MARKET, BY INDICATION
- 8.1 Indication Summary
- 8.2 Market Attractive Index
- 8.3 Global Immunotherapy Market, by Indication (2019-2032)
- SECTION 9 - GLOBAL IMMUNOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION
- 9.1 Route of Administration Summary
- 9.2 Market Attractive Index
- 9.3 Global Immunotherapy Market, by Route of Administration (2019-2032)
- SECTION 10 - GLOBAL IMMUNOTHERAPY MARKET, BY END-USE
- 10.1 End-use Summary
- 10.2 Market Attractive Index
- 10.3 Global Immunotherapy Market, by End-use (2019-2032)
- SECTION 11 - GLOBAL IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL
- 11.1 Distribution Channel Summary
- 11.2 Market Attractive Index
- 11.3 Global Immunotherapy Market, by Distribution Channel (2019-2032)
- SECTION 12 - GLOBAL IMMUNOTHERAPY MARKET, BY GEOGRAPHY
- 12.1 Regional Summary
- 12.2 Market Attractive Index
- 12.3 Global Immunotherapy Market, by Geography (2019-2032)
- SECTION 13 - NORTH AMERICA IMMUNOTHERAPY MARKET
- 13.1 North America Summary
- 13.2 Market Attractive Index
- 13.3 North America Immunotherapy Market, by Type (2019-2032)
- 13.4 North America Immunotherapy Market, by Cancer (2019-2032)
- 13.5 North America Immunotherapy Market, by Indication (2019-2032)
- 13.6 North America Immunotherapy Market, by Route of Administration (2019-2032)
- 13.7 North America Immunotherapy Market, by End-use (2019-2032)
- 13.8 North America Immunotherapy Market, by Distribution Channel (2019-2032)
- 13.9 North America Immunotherapy Market, by Country (2019-2032)
- 13.9.1 U.S.
- 13.9.2 Canada
- 13.9.3 Mexico
- 13.9.4 Rest of North America
- SECTION 14 - EUROPE IMMUNOTHERAPY MARKET
- 14.1 Europe Summary
- 14.2 Market Attractive Index
- 14.3 Europe Immunotherapy Market, by Type (2019-2032)
- 14.4 Europe Immunotherapy Market, by Cancer (2019-2032)
- 14.5 Europe Immunotherapy Market, by Indication (2019-2032)
- 14.6 Europe Immunotherapy Market, by Route of Administration (2019-2032)
- 14.7 Europe Immunotherapy Market, by End-use (2019-2032)
- 14.8 Europe Immunotherapy Market, by Distribution Channel (2019-2032)
- 14.9 Europe Immunotherapy Market, by Country (2019-2032)
- 14.9.1 Germany
- 14.9.2 U.K.
- 14.9.3 France
- 14.9.4 Italy
- 14.9.5 Spain
- 14.9.6 Russia
- 14.9.7 The Netherlands
- 14.9.8 Belgium
- 14.9.9 Turkey
- 14.9.10 Rest of Europe
- SECTION 15 - ASIA-PACIFIC IMMUNOTHERAPY MARKET
- 15.1 Asia-Pacific Summary
- 15.2 Market Attractive Index
- 15.3 Asia-Pacific Immunotherapy Market, by Type (2019-2032)
- 15.4 Asia-Pacific Immunotherapy Market, by Cancer (2019-2032)
- 15.5 Asia-Pacific Immunotherapy Market, by Indication (2019-2032)
- 15.6 Asia-Pacific Immunotherapy Market, by Route of Administration (2019-2032)
- 15.7 Asia-Pacific Immunotherapy Market, by End-use (2019-2032)
- 15.8 Asia-Pacific Immunotherapy Market, by Distribution Channel (2019-2032)
- 15.9 Asia-Pacific Immunotherapy Market, by Country (2019-2032)
- 15.9.1 China
- 15.9.2 India
- 15.9.3 Japan
- 15.9.4 South Korea
- 15.9.5 Singapore
- 15.9.6 Malaysia
- 15.9.7 Australia
- 15.9.8 Thailand
- 15.9.9 Philippines
- 15.9.10 Rest of Asia-Pacific
- SECTION 16 - SOUTH AMERICA IMMUNOTHERAPY MARKET
- 16.1 South America Summary
- 16.2 Market Attractive Index
- 16.3 South America Immunotherapy Market, by Type (2019-2032)
- 16.4 South America Immunotherapy Market, by Cancer (2019-2032)
- 16.5 South America Immunotherapy Market, by Indication (2019-2032)
- 16.6 South America Immunotherapy Market, by Route of Administration (2019-2032)
- 16.7 South America Immunotherapy Market, by End-use (2019-2032)
- 16.8 South America Immunotherapy Market, by Distribution Channel (2019-2032)
- 16.9 South America Immunotherapy Market, by Country (2019-2032)
- 16.9.1 Brazil
- 16.9.2 Argentina
- 16.9.3 Chile
- 16.9.4 Colombia
- 16.9.5 Rest of South America
- SECTION 17 - MIDDLE EAST AND AFRICA IMMUNOTHERAPY MARKET
- 17.1 Middle East and Africa Summary
- 17.2 Market Attractive Index
- 17.3 Middle East and Africa Immunotherapy Market, by Type (2019-2032)
- 17.4 Middle East and Africa Immunotherapy Market, by Cancer (2019-2032)
- 17.5 Middle East and Africa Immunotherapy Market, by Indication (2019-2032)
- 17.6 Middle East and Africa Immunotherapy Market, by Route of Administration (2019-2032)
- 17.7 Middle East and Africa Immunotherapy Market, by End-use (2019-2032)
- 17.8 Middle East and Africa Immunotherapy Market, by Distribution Channel (2019-2032)
- 17.9 Middle East and Africa Immunotherapy Market, by Country (2019-2032)
- 17.9.1 Kingdom of Saudi Arabia
- 17.9.2 South Africa
- 17.9.3 U.A.E.
- 17.9.4 Egypt
- 17.9.5 Rest of Middle East and Africa
- SECTION 18 - COMPANY SHARE ANALYSIS
- 18.1 Global Immunotherapy Market, Company Share Analysis
- 18.2 North America Immunotherapy Market, Company Share Analysis
- 18.3 Europe Immunotherapy Market, Company Share Analysis
- 18.4 Asia-Pacific Immunotherapy Market, Company Share Analysis
- SECTION 19 - COMPANY PROFILES
- 19.1 Pfizer Inc
- 19.1.1 Company Snapshot
- 19.1.2 Financial Overview
- 19.1.3 Product Portfolio
- 19.1.4 Recent Developments
- 19.2 Astra Zeneca
- 19.2.1 Company Snapshot
- 19.2.2 Financial Overview
- 19.2.3 Product Portfolio
- 19.2.4 Recent Developments
- 19.3 Merck and Co
- 19.3.1 Company Snapshot
- 19.3.2 Financial Overview
- 19.3.3 Product Portfolio
- 19.3.4 Recent Developments
- 19.4 F-Hoffman-La Roche
- 19.4.1 Company Snapshot
- 19.4.2 Financial Overview
- 19.4.3 Product Portfolio
- 19.4.4 Recent Developments
- 19.5 Bristol Myers Squibb Company
- 19.5.1 Company Snapshot
- 19.5.2 Financial Overview
- 19.5.3 Product Portfolio
- 19.5.4 Recent Developments
- 19.6 Novartis AG
- 19.6.1 Company Snapshot
- 19.6.2 Financial Overview
- 19.6.3 Product Portfolio
- 19.6.4 Recent Developments
- 19.7 Lily
- 19.7.1 Company Snapshot
- 19.7.2 Financial Overview
- 19.7.3 Product Portfolio
- 19.7.4 Recent Developments
- 19.8 Johnson and Johnson
- 19.8.1 Company Snapshot
- 19.8.2 Financial Overview
- 19.8.3 Product Portfolio
- 19.8.4 Recent Developments
- 19.9 Immunocore
- 19.9.1 Company Snapshot
- 19.9.2 Financial Overview
- 19.9.3 Product Portfolio
- 19.9.4 Recent Developments
- 19.10 BioNTech
- 19.10.1 Company Snapshot
- 19.10.2 Financial Overview
- 19.10.3 Product Portfolio
- 19.10.4 Recent Developments
- SECTION 20 - RELATED REPORTS
- SECTION 20 - DISCLAIMER
RESEARCH METHODOLOGY
The research methodology employed in Uniprism Market Research involves four basic steps namely research and data collection, data pre-processing, modeling and forecasting, quality assurance and output.
RESEARCH AND DATA COLLECTION
A tripod model research technique is followed for research and data collection in which various approaches such as primary research, secondary research, and product mapping are considered.
Primary research basically involves the process of conducting personalized interviews with market related professionals of major market players, investors, distributors, vendors and many more.
The secondary research include data published by government, annual reports, press releases, investor presentations of companies, white papers, certified publications, annual manufacturing limit of the respective industries related to the market, production consumption analysis of certain products respective to the market and many more.
Below mention are few of the sources which we have considered while estimating the market size:
For instance,
- Research articles published on Technium
- Science and MDPI
- Research publications by government approved associations and societies
Product mapping means the process of mapping the list of products that a key player contributes to the market as well as estimating the revenue of those products in order to define the Global Company share analysis of the respective Global Company in global, regional, and country level markets.
DATA PRE-PROCESSING
The term "data pre-processing" refers to the collection of procedures and methods used to clean, modify, and make ready for analysis the raw data gathered during research and data collection. The completion of this phase is necessary to guarantee that the data are reliable, consistent, and appropriate for statistical analysis and other data-driven tasks. The data pre-processing ensures that the information gathered from research and data collection is comparable and expressed in standard units, by the integration of missing data pointers and algorithmic approaches.
MODELING AND FORECASTING
The process of developing mathematical, statistical, or computational representations of real-world occurrences or relationships is known as modelling. These models are intended to replicate and explain market interactions, interdependence, and dynamics. These models are used by Uniprism Market Research to acquire a better knowledge of numerous market characteristics such as customer preferences, pricing elasticity, competition dynamics, and more. Depending on the individual study aims, many types of models are utilized, such as regression models, econometric models, decision tree models, and machine learning models.
Forecasting is the process of predicting future market conditions, trends, and occurrences using past data and models. Forecasting is used by Uniprism Market Research to estimate future sales, demand for products or services, market growth, and other important performance metrics. Forecasting accurately can assist organizations in making educated decisions about resource allocation, pricing, inventory management, and marketing tactics.
We create standardized bottom-up or top-down models that scale by leveraging data science and machine learning technology. All our market models consider the unique market characteristics of each country. Forecasting is based on major market indicators and a combination of traditional methodologies, such as exponential smoothing, time series analysis, regression analysis, and more modern techniques such as machine learning algorithms are all forecasting methodologies. The method chosen is determined on the nature of the data and the specific forecasting aims.
QUALITY ASSURANCE AND OUTPUT
Quality assurance and output involves the process of validation, adjustments, further publications of key market indicators. Extensive plausibility and consistency tests are performed on derived time series to ensure the high degree of quality of our market analysis. This quality assurance procedure also includes rigorous inspection, validation, and editing by an experienced management team to assure the dependability of the published data.